Biotechnology

Moleculin Biotech

Moleculin Biotech released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 0 and EPS of USD -61.5203

Moleculin Biotech released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.0214 (forecast USD -6.5833)

Moleculin Biotech Enters into Research Agreement with UNC Chapel Hill for Annamycin Pancreatic Cancer Therapy

Moleculin Biotech Obtains Annamycin Patent in Australia

Moleculin Biotech Launches Annamycin Clinical Trial for Late-Stage Pancreatic Cancer

Moleculin Biotech Receives Patent Allowance Notice for Liposomal Annamycin

Moleculin Biotech released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0911 (forecast USD -0.4033)

Moleculin Biotech released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -47.0917

Moleculin Biotech Signs $6.5 Million Market Offering Agreement

Moleculin Biotech Expands AML Clinical Trial Sites

Moleculin Biotech Receives Nasdaq Delisting Warning

Moleculin Biotech CEO Buys Company Stock

Moleculin Biotech Files for Public Offering with Warrants

HC Wainwright Reiterates Buy Rating on Moleculin Biotech

Moleculin Biotech's Cancer Drug Annamycin Receives Positive FDA Feedback and Approval

Moleculin Biotech Annamycin Trial Fails to Reach Complete Remission, Stock Dips

Moleculin Biotech Receives NASDAQ Noncompliance Notice

Moleculin Initiates Annamycin Phase III Trial

Moleculin Biotech released FY2025 Q1 earnings on May 13 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.22 (forecast USD -13.875)

Moleculin Biotech's Annamycin Receives EMA Approval for Late-Stage Studies

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap